Atossa Therapeutics (FRA:YAG2) Other Operating Expense : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Other Operating Expense?

Atossa Therapeutics's Other Operating Expense for the three months ended in Sep. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Atossa Therapeutics's quarterly Other Operating Expense declined from Mar. 2024 (€0.00 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€0.00 Mil).

Atossa Therapeutics's annual Other Operating Expense stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Atossa Therapeutics Other Operating Expense Historical Data

The historical data trend for Atossa Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Other Operating Expense Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

Atossa Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Atossa Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Atossa Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines

No Headlines